The use of social media is now so widespread that professional healthcare organizations have developed guidelines for its use. One of the most recent organizations to create utilization guidelines is the American Congress of Obstetricians and Gynecologists (ACOG), which released its guidelines in April 2015. Other guidelines are available from state medical boards, and the American Medical Association released a statement on the topic in 2010. The American Nurses Association (ANA) released a tool kit, which contain the ANA’s social networking principles, tips for nurses using social media, social media webinar, and a fact sheet.
ANA’s principles include not transmitting or posting identifiable patient information, observing patient-nurse boundaries, and being aware that colleagues and others have the ability to view what is posted. Nurses should utilize privacy settings and ideally, have separate personal and professional online accounts. Nurses also need to bring harmful content to the attention of appropriate individuals or authorities. The ANA notes that misuse of social media can not only damage the individual nurse’s reputation, but may damage the reputation of the nursing profession as well. The toolkit is available at http://www.nursingworld.org/socialnetworkingtoolkit.aspx.
Social Media: Risks and Benefits
The use of social media is now so widespread that professional healthcare organizations have developed guidelines for its use.
The use of social media is now so widespread that professional healthcare organizations have developed guidelines for its use. One of the most recent organizations to create utilization guidelines is the American Congress of Obstetricians and Gynecologists (ACOG), which released its guidelines in April 2015. Other guidelines are available from state medical boards, and the American Medical Association released a statement on the topic in 2010. The American Nurses Association (ANA) released a tool kit, which contain the ANA’s social networking principles, tips for nurses using social media, social media webinar, and a fact sheet.
ANA’s principles include not transmitting or posting identifiable patient information, observing patient-nurse boundaries, and being aware that colleagues and others have the ability to view what is posted. Nurses should utilize privacy settings and ideally, have separate personal and professional online accounts. Nurses also need to bring harmful content to the attention of appropriate individuals or authorities. The ANA notes that misuse of social media can not only damage the individual nurse’s reputation, but may damage the reputation of the nursing profession as well. The toolkit is available at http://www.nursingworld.org/socialnetworkingtoolkit.aspx.
Newsletter
Stay up to date on recent advances in oncology nursing and patient care.
Opinion: Targeted Therapy Plus Immunotherapy is Promising for ATC
Oncology nurses can encourage clinical trial enrollment for patients with anaplastic thyroid cancer, a rare and aggressive cancer type.
What New Cancer Drugs Were Approved in 2023?
In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.
Zanubrutinib Shows Potential Efficacy Edge in High-Risk R/R CLL, Analysis Finds
A network meta-analysis suggests zanubrutinib may offer improved efficacy over other BTK inhibitors for patients with high-risk relapsed/refractory CLL.
Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.
FDA Declines Breakthrough Status, Halts Itolizumab’s Path Forward in Acute GVHD
The FDA’s decision not to grant breakthrough designation or accelerated approval for itolizumab in acute GVHD has led to the discontinuation of the pivotal phase 3 EQUATOR trial.
As-Expected Ruxolitinib Starting Dose Outperforms Lower Dosage in Myelofibrosis
Both those receiving either expected or less-than-expected starting dosages of ruxolitinib for myelofibrosis treatment reduced daily dosages over 12 months.
Opinion: Targeted Therapy Plus Immunotherapy is Promising for ATC
Oncology nurses can encourage clinical trial enrollment for patients with anaplastic thyroid cancer, a rare and aggressive cancer type.
What New Cancer Drugs Were Approved in 2023?
In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.
Zanubrutinib Shows Potential Efficacy Edge in High-Risk R/R CLL, Analysis Finds
A network meta-analysis suggests zanubrutinib may offer improved efficacy over other BTK inhibitors for patients with high-risk relapsed/refractory CLL.
Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.
FDA Declines Breakthrough Status, Halts Itolizumab’s Path Forward in Acute GVHD
The FDA’s decision not to grant breakthrough designation or accelerated approval for itolizumab in acute GVHD has led to the discontinuation of the pivotal phase 3 EQUATOR trial.
As-Expected Ruxolitinib Starting Dose Outperforms Lower Dosage in Myelofibrosis
Both those receiving either expected or less-than-expected starting dosages of ruxolitinib for myelofibrosis treatment reduced daily dosages over 12 months.
Latest Conference Coverage
Cilta-Cel Improves QOL, Extends Treatment Breaks vs SOC in R/R Myeloma
Acupuncture Use in BC Predicted by Social Determinants of Health
Variability Found in PROs, Gene Expression During AML Induction Chemo
Blinatumomab-Linked ICANS Cases Higher Than Previously Reported